

Cynomolgus TNFRSF8(CD30) Protein; hFc Tag

Product Information


| | |
|------------------------|---|
| Product Name | Cynomolgus TNFRSF8(CD30) Protein; hFc Tag |
| Storage temp | Store at $\leq -70^{\circ}\text{C}$, stable for 6 months after receipt. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Catalog# / Size | GM-88429RP-100 / 100 μg GM-88429RP-1000 / 1 mg |

Protein Information

| | |
|---------------------------|--|
| Alternative Names | TNFRSF8, CD30, D1S166E, Ki-1 |
| Source | Cynomolgus TNFRSF8(CD30) Protein; hFc Tag (GM-88429RP) is expressed from human 293 cells (HEK-293). It contains AA Ala 27 - Pro 394 (Accession # A0A2K5VW07). This protein carries a human IgG1 Fc tag at the C-terminus. |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/ μg , determined by LAL gel clotting assay |
| Predicted Mol Mass | 64.7 KDa |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Description | TNFRSF8, also known as CD30, is a type I transmembrane receptor in the tumor necrosis factor receptor (TNFR) superfamily. It is variably expressed on activated T cells, certain B cells, and a subset of malignancies such as Hodgkin lymphoma and anaplastic large cell lymphoma. CD30 functions as a co-stimulatory receptor involved in cell proliferation, survival, and differentiation signals. It is also used as a diagnostic and therapeutic target in CD30-positive diseases. Other aliases include D1S166E and Ki-1. CD30 signaling is initiated upon trimerization or clustering of the receptor, leading to recruitment of adaptor proteins and activation of downstream pathways such as NF- κB , MAPK (ERK, JNK), and PI3K-Akt. This signaling promotes cell survival, proliferation, and cytokine production, particularly in activated T cells and certain neoplastic cells. Dysregulated CD30 signaling can contribute to pathologic immune responses and tumorigenesis, making CD30 a valuable target for monoclonal antibodies and targeted therapies. |


Version:4.0

SDS-PAGE




On SDS-PAGE under non-reducing (NR) condition and reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA



Cynomolgus TNFRSF8(CD30) Protein; hFc Tag (Catalog # GM-88429RP) was immobilized at 2 $\mu\text{g}/\text{ml}$ (100 $\mu\text{L}/\text{well}$). Increasing concentrations of Anti-H_TNFRSF8(CD30) hIgG1 Antibody(Brentuximab) (Catalog # GM-28856AB) were added.



Cynomolgus TNFRSF8(CD30) Protein; hFc Tag (Catalog # GM-88429RP) was immobilized at 2 $\mu\text{g}/\text{ml}$ (100 $\mu\text{L}/\text{well}$). Increasing concentrations of Anti-CD30 hIgG1 Reference Antibody(Brebio) (Catalog # GM-87698MAB) were added.